Continuous infusion of coagulation factor concentrates during intensive treatment

Abstract

In clinical management of bleeds and surgical procedures in patients suffering from bleeding disorders either repetitive bolus injections (BI) or continuous infusion (CI) can be used for coagulation factor replacement. Continuous infusion seems to be an attractive route of administration and may be considered if replacement therapy is required for more than 3 days. The strongest argument favouring continuous infusion is its superiority in providing the patient with a safe and constant level of the deficient coagulation factor by balancing input with clearance. Furthermore, several studies have shown that coagulation factor consumption may be reduced by CI compared to repetitive bolus injections (BI) since unnecessary peaks of factor level are avoided. Concerns have been raised whether continuous infusion of coagulation concentrates is associated with an increased risk of developing inhibitors. However, available data have so far not shown an increased risk for inhibitor development in severe haemophilia patients with more than 50 exposure days of coagulation factor concentrates. Further, previously reported complications when using CI such as phlebitis at the infusion site and pump failure are nowadays very seldom seen when small amounts of heparin are added to the infusion bag, and increased quality of the pumps are available. Over the last decades, numerous reports have confirmed CI to be a safe and effective mode of coagulation factor replacement even in the most challenging surgical procedures, such as total joint arthroplasties. K E Y W O R D Scoagulation factor concentrates, continuous infusion, haemophilia A, haemophilia B, rFVIIa

Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries

“…Pump failure leading to an unexpected and dangerous drop in coagulation factor level are very seldom reported due to increased quality of pumps used in current practice. 12 There were no incidences of pump failure in our study.…”

“…The maintenance dose of CI was adjusted according to clearance recalculated daily according to actual control of FVIII levels using the formula: Clearance (mL/kg/h) = infusion rate (IU/kg/h)/measured factor level (IU/mL). 12 Testing for inhibitors to FVIII was performed on consecutive follow-up visits using the Nijmegen-Bethesda assay.…”

Expert consensus on the diagnosis and treatment of heat stroke in China

“…The following conditions should be met when using rVII to stop bleeding: 1) acidosis, hypothermia and hypocalcemia have been corrected; 2) hematocrit > 24%, platelet count > 50 × 10 9 /L and Fib level > 1.5 g/L. The initial dose of rVII should be 200 μg/ kg, and depending on the presence of bleeding, 100 μg/ kg rVII can be administered at an interval of 2 h. The drug can be discontinued according to the presence of bleeding and the results of blood coagulation tests [91].…”

Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

“…Depending on the state of the bleeding, rVII 100 μg/kg can be given at intervals of 2 hours. The drug can be discontinued based on the amount of bleeding and the coagulation test results [43].…”